Background: The assessment of serum neurofilament light chain (sNfL) concentration in multiple sclerosis (MS) is a useful tool for predicting clinical outcomes and assessing treatment response. However, its use in clinical practice is still limited. We aimed to assess how measurement of sNfL influences neurologists' treatment decisions in MS.
Methods: We conducted a cross-sectional, web-based study in collaboration with the Spanish Society of Neurology. Neurologists involved in MS care were presented with different simulated case scenarios of patients experiencing either their first demyelinating MS event or a relapsing-remitting MS. The primary outcome was therapeutic inertia (TI), defined as the absence of treatment initiation or intensification despite elevated sNfL levels. Nine cases were included to estimate the TI score (range 0-9, where higher values represented a higher degree of TI).
Results: A total of 116 participants were studied. Mean age (standard deviation-SD) was 41.9 (10.1) years, 53.4 % male. Seventy-eight (67.2 %) were neurologists fully dedicated to the care of demyelinating disorders. Mean (SD) TI score was 3.65 (1.01). Overall, 92.2 % of participants (n = 107) presented TI in at least 2/9 case scenarios. The lack of full dedication to MS care (p = 0.014), preference for taking risks (p = 0.008), and low willingness to adopt evidence-based innovations (p = 0.009) were associated with higher TI scores in the multivariate analysis after adjustment for confounders.
Conclusion: TI was a common phenomenon among neurologists managing MS patients when faced with the decision to initiate or escalate treatment based on elevated sNfL levels. Identifying factors associated with this phenomenon may help optimize treatment decisions in MS care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2024.105838 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cognitive decline and neuroinflammation in a mouse model of obesity: An accelerating role of ageing.
Brain Behav Immun
December 2024
Department of Geriatrics, University Medical Center Goettingen, Robert-Koch-Str. 42, 37075 Goettingen, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, 37075 Göttingen, Germany. Electronic address:
Obesity, a pandemic, worldwide afflicts almost one billion people. Obesity and ageing share several pathological pathways leading to neurological disorders. However, due to a lack of suitable animal models, the long-term effects of obesity on age-related disorders- cognitive impairment and dementia have not yet been thoroughly investigated.
View Article and Find Full Text PDFSerum glycobiomarkers for chronic inflammatory demyelinating polyneuropathy.
Eur J Neurol
January 2025
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Article Synopsis
- The study analyzed glycan biomarkers in serum to understand their relationship with chronic inflammatory demyelinating polyneuropathy (CIDP) and treatment effects.
- Significant differences were found in N-glycan levels, particularly lower sialylated N-glycans in CIDP patients compared to healthy controls, while O-glycan levels remained unchanged.
- Lower sialylated N-glycan levels may indicate therapeutic resistance and could serve as a potential biomarker for CIDP’s pathophysiology.
Long-Term Clinical and Biological Prognostic Factors of Anti-NMDA Receptor Encephalitis in Children.
Neurol Neuroimmunol Neuroinflamm
March 2025
Pediatric Neurology Departement, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University Hospitals, Bicêtre Hospital, and Paris-Saclay University, Le Kremlin-Bicêtre.
Background And Objectives: Anti-NMDAR encephalitis (NMDARE) is a severe neurologic condition, and recently, the NMDAR Encephalitis One-Year Functional Status (NEOS) score has emerged as a 1-year prognostic tool. This study aimed to evaluate NEOS score and biomarker (neurofilament light chains [NfL], total-Tau protein, glial fibrillary acidic protein, and serum cytokines) correlation with modified Rankin Scale (mRS), cognitive impairment, and clinical recovery in pediatric NMDARE over 2 years.
Methods: In this French multicenter observational study, 104 pediatric patients with NMDARE were followed for a minimum of 2 years.
Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
Neurology
January 2025
Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco.
Background And Objective: The impact of menopause on the brain is not well understood. Hormonal changes, including puberty and pregnancy, influence the onset and course of multiple sclerosis (MS). After menopause, a worsening of MS disease trajectory measured on the clinician-rated Expanded Disability Status Scale (EDSS) was reported in some, but not all, studies.
View Article and Find Full Text PDFBlood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
JAMA Neurol
December 2024
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Importance: The temporal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) as biomarkers of disease activity for neuromyelitis optica spectrum disorder (NMOSD) remain underexplored.
Objective: To determine optimal timing for assessing sGFAP and sNfL, establish cutoff values differentiating between attacks and remissions in NMOSD, and evaluate these findings across independent cohorts.
Design, Setting, And Participants: This retrospective, longitudinal, multicenter cohort study was conducted among patients with aquaporin-4 antibody (AQP4-IgG)-positive NMOSD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!